Clinical Trial

Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of stapokibart in adolescent patients with seasonal allergic rhinitis, and observing the quality of life, Pharmakokinetics(PK), Pharmacodynamics (PD) characteristics, and immunogenicity of subjects.
Trial Details
NCT Number NCT07678931
Lead Sponsor Chengdu Kangnuoxing Biopharma,Inc.
Conditions Seasonal Allergic Rhinitis (SAR)
Enrollment 136 participants
Start Date 2026-08
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-01